CRDL: התחייבויות שוטפות של החברה Cardiol Therapeutics

Cardiol Therapeutics (CRDL) is developing clean anti-inflammatory drugs for myocarditis without side effects, utilizing digital oversight of external clinical trials. The model scales via contract manufacturing, ensuring high profitability against fixed development costs. The short-term debt history on the GURU.Markets portal demonstrates the current load, where 0.00 shows the current volume of short-term liabilities.

The high macro-resilience of Cardiol Therapeutics (CRDL) is driven by the non-cyclical nature of cardiology drug development, where success depends on clinical trials rather than market conditions. An analysis of current short-term liabilities allows for an assessment of cash flow gap risks via the amount of debt maturing within one year, which is critical for ensuring the company's liquidity during periods of intensive research.